Sickle Cell

Hydroxyurea therapy was associated with decreased rates of retinal thinning and could be a protective factor.

New findings show that 100% of patients receiving voxelotor 1500 mg group experienced improvements in their leg ulcers—compared to 63% in the placebo group.

Patients with sickle cell disease who are undernourished report higher disease severity and lower health-related quality of life scores.

Two gene therapy techniques in separate, concurrently published trials demonstrate clinical success in mitigating monogenic hemoglobinopathies.

Rodney Wilson, spokesperson from the American Red Cross, offers some final thoughts on how providers can encourage blood donations among their patients.

Elevated tricuspid reguritant velocity levels as a biomarker for SCA severity also marks response to disease modifying treatments.

Encouraging and incentivizing donations is essential to ensuring supplies of all blood types are met.

A spokesperson from American Red Cross discusses the importance of National Blood Donor Month and the challenges faced during the COVID-19 pandemic.

A new study has identified various potential clinical predictors associated with poor outcomes, including mortality, in patients with sickle cell disease.

The current literature points to the potential efficacy and safety of the anti-depressant drug, but more research is needed to verify its role in managing pain caused by vaso-occlusive crises.

New one-year data makes history as the first to indicate the superiority of a one-injection gene therapy versus Factor VIII prophylaxis.

The US Assistant Secretary for Health offers perspective on this past year in sickle cell care and the potential for its future.

The burden of cardiovascular disease is particularly high in African Americans, a population that typically faces health disparities.

ADM Giroir, MD, discusses additional examples of efforts to optimize sickle cell care.

The US Assistant Secretary for Health provides a top-down, government-level perspective on how sickle cell care has advanced in recent years.

The past few years have seen emerging therapies, but the tragedies of 2020 have only amplified the healthcare inequalities associated with sickle cell care.